• Alfuzosin HCl in BPH Research: Protocols and Innovations

  2026-06-03

  Alfuzosin HCl unlocks precise modeling of the α1-adrenergic receptor signaling pathway for benign prostatic hyperplasia research, empowering workflows from in vitro quantification to advanced gastroretentive formulation. Explore evidence-based protocol parameters, troubleshooting strategies, and breakthrough applications that differentiate APExBIO’s Alfuzosin Hydrochloride for translational urinary disease studies.

• Mapping Proteoform-Specific Drug Interactions In Native Memb

  2026-06-03

  This study pioneers native top-down mass spectrometry to directly characterize drug interactions with specific membrane protein proteoforms in their unmodified lipid bilayer environment. Key findings reveal that cGMP-specific phosphodiesterase type 5 inhibitors, including sildenafil, display differential binding to retinal proteoforms, emphasizing the importance of proteoform-aware drug design and the potential for minimizing off-target effects.

• Clarithromycin as a CYP3A Inhibitor in Drug Interaction Rese

  2026-06-02

  Clarithromycin is a potent CYP3A inhibitor widely used in drug-drug interaction research and pharmacokinetic studies. Its strong inhibitory effect on CYP3A impacts the metabolism of various drugs, such as statins, and necessitates precise protocol design. APExBIO supplies a rigorously characterized Clarithromycin (A4322) suitable for reliable laboratory use.

• Nutlin-3a: Advancing MDM2 Inhibition for p53 Pathway Insight

  2026-06-02

  Explore the advanced role of Nutlin-3a as a potent MDM2 inhibitor in dissecting the p53 pathway, with scientific insights into apoptosis and cancer research. Discover nuanced protocol guidance and the latest findings that inform assay design and translational oncology.

• Cell Counting Kit-8 (CCK-8): Precision for Hypoxia-Driven Ca

  2026-06-01

  Explore how Cell Counting Kit-8 (CCK-8) empowers researchers to dissect cell proliferation and chemoresistance under hypoxic conditions—a crucial challenge in cancer biology. This article offers a unique, evidence-driven perspective on CCK-8's role in advanced glioblastoma modeling and assay optimization.

• Agatoxin-IVA-Sensitive Channels in Cardiac Vagal Neuron Modu

  2026-06-01

  The reference study establishes that P/Q-type (agatoxin-IVA-sensitive) voltage-gated calcium channels are crucial for both presynaptic and postsynaptic nicotinic activation of cardiac vagal neurons. These findings clarify the specific calcium channel subtypes mediating neurotransmission in cardiac autonomic regulation, providing a refined target for mechanistic neurophysiology and potential neuroprotection strategies.

• 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine:

  2026-05-31

  Explore how 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine, a selective α2-adrenergic receptor agonist, advances immune rejection modulation in osteosarcoma recurrence research. This article uniquely dissects mechanistic insights and assay strategies for translational applications.

• Topotecan vs. Etoposide in First-Line SCLC: Mechanistic Insi

  2026-05-30

  The referenced study critically examines the use of topotecan, both alone and in combination regimens, as a first-line treatment for small cell lung cancer (SCLC), benchmarking outcomes and toxicity profiles against the conventional cisplatin-etoposide (PE) regimen. Findings emphasize the ongoing importance of DNA damage pathways in SCLC management and highlight the need for regimens with manageable, noncumulative toxicities.

• Trelagliptin Succinate: Applied Workflows in Diabetes Resear

  2026-05-29

  Trelagliptin succinate (SYR-472 succinate) uniquely combines long-acting, selective DPP-4 inhibition with multi-pathway modulation, enabling robust glucose-dependent insulin secretion assays and advanced metabolic disease models. This article distills protocol enhancements, troubleshooting strategies, and translational insights—bridging metabolic, inflammatory, and neurocognitive research.

• Amikacin (BAY416651): Advanced Roles in Resistance Mechanism

  2026-05-29

  Explore the unique utility of Amikacin (BAY416651) as a bacterial protein synthesis inhibitor in dissecting antibiotic resistance, focusing on carbapenem-resistant Enterobacter cloacae and Klebsiella pneumoniae. This article offers new depth on protocol optimization and genetic insights for resistance studies.

• Stiripentol: LDH Inhibitor for Advanced Epilepsy & Metabolic

  2026-05-28

  Stiripentol from APExBIO empowers researchers to modulate the astrocyte-neuron lactate shuttle and interrogate lactate-driven pathways in epilepsy and immunometabolism. This guide delivers actionable protocols, troubleshooting insights, and the latest translational context bridging metabolic and epigenetic assays.

• TBK1 Inhibition Alleviates Painful Diabetic Neuropathy via M

  2026-05-28

  Liao et al. (2024) reveal that TANK-binding kinase 1 (TBK1) is a central mediator of microglia pyroptosis in painful diabetic neuropathy (PDN). By demonstrating that TBK1 inhibition—via siRNA or amlexanox—attenuates PDN in mouse models, the study advances understanding of neuroimmune mechanisms in diabetes and opens new avenues for targeted therapeutic intervention.

• CA-074 Me: Selective Cathepsin B Inhibitor for Lysosomal Res

  2026-05-27

  CA-074 Me is a potent cathepsin B inhibitor used to dissect lysosomal enzyme pathways and apoptosis mechanisms. It exhibits high selectivity and cell permeability, making it valuable for TNF-α-induced liver injury and necroptosis studies. The compound’s performance and limitations are well-documented by APExBIO and recent mechanistic research.

• Stiripentol as an LDH Inhibitor: Protocols and Research Insi

  2026-05-27

  Stiripentol stands out among LDH inhibitors for its unique action on the astrocyte-neuron lactate shuttle, enabling precision in epilepsy and metabolic epigenetics research. This guide delivers actionable protocols, troubleshooting strategies, and translational insights informed by recent advances in lactate-driven immunometabolism.

• Phosbind Acrylamide: Next-Gen Phosphate-Binding for Protein

  2026-05-26

  Discover how Phosbind Acrylamide enables advanced phosphate-binding reagent workflows for precise protein phosphorylation analysis. This in-depth guide explores new scientific insights and practical assay optimization.

496 records 12/34 page Previous Next First page 上5页 1112131415 下5页 Last page